Skip to content
RecallWatchMedical Device Safety
Class IIOngoingZ-1119-2025

CareFusion 303, Inc. recalls (1) Pyxis MedStation ES

CareFusion 303, Inc.San Diego, CA, United StatesReported Feb 19, 2025 · 1 year ago
Legal News Analyst ·

Reason for recall

Software issues could potentially result in: 1) delays in accessing dispensing software application, 2) wrong therapy (dose, item, timing, etc.), or 3) unauthorized access and/or compliance related issues

Affected product

Check your device

Enter a lot, serial, REF, or UDI number from your device's label to check it against this recall's listed codes.

(1) Pyxis MedStation ES, Catalog No. 323; (2) Pyxis Anesthesia Station (PAS), Catalog No. 327; (3) Pyxis MedStation ES Tower, Catalog No. 352; (4) BD Pyxis CII Safe ES, Catalog No. 1116-00

Lot / code information

Catalog #
323
UDI
10885403512667; (2) Pyxis Anesthesia Station (PAS)
Catalog #
327
UDI
10885403477836; (3) Pyxis MedStation ES Tower
Catalog #
352
UDI
10885403512674; (4) BD Pyxis CII Safe ES
Catalog #
1116-00
UDI
10885403512605; All
Serial #
; Software Versions v1.10 and prior Affected

What the firm is doing

On January 8, 2025, the firm notified customers via email and mailed letter titled "Urgent Medical Device Correction". Firm states customers can continue to use Pyxis products in accordance with their labeling and any previously provided field action notifications, including the following guidance: 1. Facilities should establish policies and procedures for when an automated dispensing system is unavailable. 2. Device Keys can manually access unavailable drawers, but must be readily available and retrievable to adequately mitigate the risk. 3. Emergency supplies should be physically available in care areas for critical or urgent medications. 4. If using critical override mode to access contents of the device, users must use extra precautions and verify correct medications are selected. The firm anticipates releasing software update ES 1.11 beginning June 2025, which will address these software issues.

DistributionShow details

Domestic distribution nationwide. International distribution to North America, Latin America, EMEA, and Greater Asia.

Class IIWhat this means

Use of the product may cause temporary or medically reversible adverse health consequences.

Sources & references

Taylor Coteus
Legal News Analyst

Taylor Coteus is RecallWatch's Legal News Analyst, covering FDA medical-device enforcement and patient-safety litigation. He reviews every recall against the FDA's official openFDA record before it is published and is responsible for corrections and editorial accuracy.

More Class II recalls